Catalyst Pharmaceuticals reports strong Q2 2024 financial results with significant revenue growth

From GlobeNewswire: 2024-08-07 16:11:00

Catalyst Pharmaceuticals reported robust revenue performance for Q2 2024, with total revenues of $122.7 million, a YoY increase of 23.2%. FIRDAPSE net product revenues were $77.4 million, showing 19.2% growth. AGAMREE net product revenues were $8.7 million, marking a strong start. FYCOMPA net product revenues were $36.5 million, up 5.7% from the previous year.

In Q2 2024, Catalyst Pharmaceuticals reported GAAP net income of $40.8 million ($0.33 per diluted share) and non-GAAP net income of $69.6 million ($0.56 per diluted share). The company reaffirmed its 2024 total revenue guidance of $455 million – $475 million, expecting to achieve the upper end of the range. A conference call and webcast will be held on August 8, 2024, at 8:30 AM ET.

Catalyst Pharmaceuticals reported strong financial results for Q2 2024, with total net product revenues of $122.7 million, a 23.3% YoY increase. FIRDAPSE net product revenues were $77.4 million, showing impressive growth. AGAMREE, a novel corticosteroid treatment for Duchenne Muscular Dystrophy, had net product revenues of $8.7 million. FYCOMPA net product revenues were $36.5 million.

Key financial metrics for Q2 2024 include a total revenue of $122.7 million, a 23.2% YoY increase. GAAP net income was $40.8 million, and non-GAAP net income was $69.6 million. Cash and cash equivalents were $375.7 million as of June 30, 2024. Catalyst Pharmaceuticals remains committed to developing and commercializing innovative medicines to address rare diseases and continues to strengthen its financial position.



Read more at GlobeNewswire:: Catalyst Pharmaceuticals Reports Strong Second Quarter 2024